Heterocyclic compounds execute a very important role in drug design and discovery. This article provides the basic milestones of the research for pyrroloaryl and pyrroloheteroaryl based components targeting HIV viral replication cycle. Anti-HIV activity is elaborated for several classes of pyrrolo-compounds as pyrrolopyridines, pyrrolopyrimidines, pyrrolopyridazines, pyrrolobenzodiazepinones, pyrrolobenzothiazepines, pyrrolobenzoxazepinones, pyrrolophenanthridines, pyrroloquinoxalines, pyrrolotriazines, pyrroloquinolines, pyrrolopyrazinones, pyrrolothiatriazines, arylthiopyrroles and pyrrolopyrazolones targeting two essential HIV enzymes, reverse transcriptase and integrase as well as attachment/fusion of HIV virons to the host CD-4 cell. Such attempts were resulted in a discovery of highly potent anti-HIV agents suitable for clinical trials, for example, BMS-378806, BMS-585248, BMS-626529, BMS-663068, BMS-488043 and BMS-663749, etc. as anti-HIV attachment agents, triciribine, QX432, BI-1 and BI-2 as HIV RT inhibitors which are in preclinical or clinical development. Mechanism of action of compounds presented in this article towards the suppression of HIV attachment/fusion as well as against the activities of HIV enzymes reverse transcriptase and integrase has been discussed. Relationships of new compounds' molecular framework and HIV viral target has been overviewed in order to facilitate further construction of promising anti-HIV agents in future drug discovery process.

Laboratory of Growth Regulators Centre of the Region Haná for Biotechnological and Agricultural Research Institute of Experimental Botany ASCR and Palacký University Šlechtitelů 27 783 71 Olomouc Czech Republic

Organic Research Laboratory Department of Bioresources and Food Science College of Life and Environmental Sciences Konkuk University Seoul 143 701 South Korea

000      

00000naa a2200000 a 4500

001      

bmc16020625

003      

CZ-PrNML

005      

20160726093407.0

007      

ta

008      

160722s2015 enk f 000 0|eng||

009      

AR

024    7_

$a 10.1016/j.bmc.2015.06.016 $2 doi

024    7_

$a 10.1016/j.bmc.2015.06.016 $2 doi

035    __

$a (PubMed)26116177

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a enk

100    1_

$a Patel, Rahul V $u Laboratory of Growth Regulators, Centre of the Region Haná for Biotechnological and Agricultural Research, Institute of Experimental Botany ASCR & Palacký University, Šlechtitelů 27, 783 71 Olomouc, Czech Republic. Electronic address: rahul.svnit11@gmail.com.

245    10

$a Pyrroloaryls and pyrroloheteroaryls: Inhibitors of the HIV fusion/attachment, reverse transcriptase and integrase / $c RV. Patel, SW. Park,

520    9_

$a Heterocyclic compounds execute a very important role in drug design and discovery. This article provides the basic milestones of the research for pyrroloaryl and pyrroloheteroaryl based components targeting HIV viral replication cycle. Anti-HIV activity is elaborated for several classes of pyrrolo-compounds as pyrrolopyridines, pyrrolopyrimidines, pyrrolopyridazines, pyrrolobenzodiazepinones, pyrrolobenzothiazepines, pyrrolobenzoxazepinones, pyrrolophenanthridines, pyrroloquinoxalines, pyrrolotriazines, pyrroloquinolines, pyrrolopyrazinones, pyrrolothiatriazines, arylthiopyrroles and pyrrolopyrazolones targeting two essential HIV enzymes, reverse transcriptase and integrase as well as attachment/fusion of HIV virons to the host CD-4 cell. Such attempts were resulted in a discovery of highly potent anti-HIV agents suitable for clinical trials, for example, BMS-378806, BMS-585248, BMS-626529, BMS-663068, BMS-488043 and BMS-663749, etc. as anti-HIV attachment agents, triciribine, QX432, BI-1 and BI-2 as HIV RT inhibitors which are in preclinical or clinical development. Mechanism of action of compounds presented in this article towards the suppression of HIV attachment/fusion as well as against the activities of HIV enzymes reverse transcriptase and integrase has been discussed. Relationships of new compounds' molecular framework and HIV viral target has been overviewed in order to facilitate further construction of promising anti-HIV agents in future drug discovery process.

650    _2

$a látky proti HIV $x chemie $x farmakologie $7 D019380

650    _2

$a objevování léků $7 D055808

650    _2

$a HIV $x účinky léků $x enzymologie $x fyziologie $7 D006678

650    _2

$a inhibitory HIV fúze $x chemie $x farmakologie $7 D023581

650    _2

$a HIV infekce $x farmakoterapie $x virologie $7 D015658

650    _2

$a HIV-integrasa $x metabolismus $7 D019427

650    _2

$a inhibitory HIV-integrasy $x chemie $x farmakologie $7 D019428

650    _2

$a lidé $7 D006801

650    _2

$a pyrroly $x chemie $x farmakologie $7 D011758

650    _2

$a reverzní transkriptasa $x metabolismus $7 D012194

650    _2

$a inhibitory reverzní transkriptasy $x chemie $x farmakologie $7 D018894

650    _2

$a replikace viru $x účinky léků $7 D014779

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

655    _2

$a přehledy $7 D016454

700    1_

$a Park, Se Won $u Organic Research Laboratory, Department of Bioresources and Food Science, College of Life and Environmental Sciences, Konkuk University, Seoul 143 701, South Korea.

773    0_

$w MED00000769 $t Bioorganic & medicinal chemistry $x 1464-3391 $g Roč. 23, č. 17 (2015), s. 5247-63

856    41

$u https://pubmed.ncbi.nlm.nih.gov/26116177 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20160722 $b ABA008

991    __

$a 20160726093626 $b ABA008

999    __

$a ok $b bmc $g 1155295 $s 945153

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2015 $b 23 $c 17 $d 5247-63 $e 20150614 $i 1464-3391 $m Bioorganic & medicinal chemistry $n Bioorg Med Chem $x MED00000769

LZP    __

$a Pubmed-20160722